Sanitary Act. After the approval in 2016 by the Spanish Agency for Medicines and Health Products (AEMPS) of two biosimilar anti-TNF drugs from Biogen, this biotechnology company has taken stock of its "best" year in Spain, in an act in which , together with health professionals, made a staunch defense of these drugs.